New Treatment Option for Women at Risk of Fragility Fractures

    loading  Checking for direct PDF access through Ovid

Abstract

A randomized trial demonstrated a reduced risk of fragility fractures in high-risk women with osteoporosis treated monthly with the monoclonal antibody romosozumab compared with weekly alendronate.

Related Topics

    loading  Loading Related Articles